5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $241000 | -$24M | -262.7% | -9240.7% | -$18M | — | $4M |
| 2024 | $225000 | -$21M | -229.8% | -8558.2% | -$19M | — | $5M |
| 2023 | $316000 | -$30M | -149.7% | -5809.8% | -$17M | — | $4M |
| 2022 | $237000 | -$16M | -110.1% | -3673.4% | -$9M | — | $183000 |
| 2021 | — | -$251633 | — | — | — | — | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $39000 | -$4M | -702.6% | -15279.5% | — | — | $25M |
| Dec '25 | $75000 | -$7M | -181.3% | -8513.3% | -$6M | — | $4M |
| Sep '25 | $42000 | -$6M | -383.3% | -13590.5% | -$4M | — | $4M |
| Jun '25 | $78000 | -$6M | -200.0% | -6500.0% | -$4M | — | $5M |
| Mar '25 | $46000 | -$5M | -391.3% | -11102.2% | -$4M | — | $5M |
| Dec '24 | $42000 | -$5M | -273.8% | -10831.0% | -$5M | — | $5M |
| Sep '24 | $56000 | -$6M | -233.9% | -8878.6% | -$4M | — | $4M |
| Jun '24 | $68000 | -$4M | -260.3% | -7135.3% | — | — | $2M |
| Mar '24 | $59000 | -$6M | -159.3% | -8278.0% | — | — | $5M |
| Dec '23 | $95000 | -$5M | -146.3% | -7076.8% | -$11M | — | $4M |
| Sep '23 | $80000 | $2M | -136.3% | -4231.3% | $1M | — | $17M |
| Jun '23 | $63000 | -$13M | -157.1% | -7111.1% | -$4M | — | $68000 |
| Mar '23 | $78000 | -$13M | -124.4% | -4834.6% | -$3M | — | $1M |
| Dec '22 | $20000 | -$11M | -655.0% | -14530.0% | -$2M | — | $183000 |
| Sep '22 | $57000 | -$1M | -86.0% | -3150.9% | — | — | $609000 |
| Jun '22 | — | -$1M | — | — | — | — | $476948 |
| Mar '22 | — | $12M | — | — | — | — | $127105 |
| Dec '21 | — | -$5M | — | — | — | — | $1M |
| Sep '21 | — | $6M | — | — | — | — | $1M |
| Jun '21 | — | $371144 | — | — | — | — | $2M |
How the market has priced COCH against its own fundamentals since 2023-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, Envoy Medical, Inc.'s revenue has grown 0.6% per year. These are computed facts, not advice.
As of FY2025, Envoy Medical, Inc. reported — of total debt against $4M of cash; operating income covered interest expense -14.0×.
In FY2025, gross margin was -262.7%, operating margin -9240.7%, and net margin -9857.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.